StockNews.com Upgrades Cyclacel Pharmaceuticals (NASDAQ:CYCC) to Hold

Cyclacel Pharmaceuticals (NASDAQ:CYCC) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Tuesday.

A number of other equities analysts have also recently issued reports on the company. Brookline Capital Management cut Cyclacel Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, December 19th. Roth Mkm boosted their target price on shares of Cyclacel Pharmaceuticals from $16.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, December 19th.

Cyclacel Pharmaceuticals Trading Up 4.2 %

Shares of CYCC opened at $2.00 on Tuesday. The firm’s fifty day simple moving average is $2.43 and its two-hundred day simple moving average is $4.27. Cyclacel Pharmaceuticals has a 12 month low of $1.82 and a 12 month high of $13.20. The stock has a market capitalization of $1.68 million, a P/E ratio of -0.07 and a beta of 0.56.

Institutional Investors Weigh In On Cyclacel Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Schonfeld Strategic Advisors LLC raised its position in shares of Cyclacel Pharmaceuticals by 25.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 770,400 shares of the biotechnology company’s stock worth $514,000 after purchasing an additional 155,200 shares during the period. Millennium Management LLC raised its holdings in Cyclacel Pharmaceuticals by 6.5% during the fourth quarter. Millennium Management LLC now owns 208,062 shares of the biotechnology company’s stock worth $139,000 after buying an additional 12,617 shares during the last quarter. HRT Financial LP bought a new position in shares of Cyclacel Pharmaceuticals in the fourth quarter valued at $27,000. Two Sigma Investments LP bought a new position in shares of Cyclacel Pharmaceuticals in the third quarter valued at $98,000. Finally, Renaissance Technologies LLC grew its holdings in shares of Cyclacel Pharmaceuticals by 166.0% during the third quarter. Renaissance Technologies LLC now owns 167,600 shares of the biotechnology company’s stock valued at $245,000 after buying an additional 104,600 shares during the last quarter. Institutional investors and hedge funds own 23.58% of the company’s stock.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.